Purchase this article with an account.
M. Tanaka, M. Kiyokawa, J. Inoue, A. Mizota, A. Murakami, A. Ichinose, M. Souri; Effect of Intravitreal Injection of Autologous Plasmin Alone in Eyes With Diabetic Maculopathy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5578.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:Plasmin is a protein kinase, and an intravitreal injection of plasmin can induce posterior vitreous detachment (PVD). The efficacy of autologous plasmin derived from patients own serum, as an adjunct to vitreous surgery has been reported for macular hole or diabetic retinopathy. The purpose of this study was to show the effect of intravitreal injection of autologous plasmin alone in eyes with diabetic maculopathy. Methods: Plasmin was derived from the patient’s own serum as previously reported. Eight eyes of 6 cases with diabetic maculopathy were injected with autologous plasmin. The dosage of plasmin ranged from 0.8 to 2.0 IUs. The visual acuity, visual field, OCT, B–mode ultrasonography, and ERGs were measured before and after the plasmin injection. Results: In all cases, a PVD developed within one day after the injection. A mild inflammation was observed in one patient injected with 2.0 IU of plasmin, but the inflammation was resolved within 3 days. In 4 eyes, the visual acuity recovered more than 2 lines. The OCT–determined retinal thickness was reduced, and the ERGs were not changed in all cases. Conclusions: Autologous plasmin injection alone might be useful to treat diabetic maculopathy.
This PDF is available to Subscribers Only